Diligence memo · auto-generated · as of July 2, 2026
Trimel Biopharma Holdings Inc.
Trimel Biopharma Holdings Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Trimel Biopharma Holdings Inc. operates in Pharmaceuticals, based in DURANTS, CHRIST CHURCH.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Trimel Biopharma Holdings Inc. has raised $7.0M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.3M on 2011-07-14.
Most recent recorded round closed around 2011-07-14.
Valuation (modeled)modeled
Provath models Trimel Biopharma Holdings Inc. at approximately $194M (range $7.2M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.08× the median modeled value of Series A Pharmaceuticals companies in 2010–2012 (57 peers) — value vs value, same stage and era. Within the normal band (108% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 15.0 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 14.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 48% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 68% of those peers.
Closest niche peers: Satori Pharmaceuticals Inc, Labrys Biologics, Inc., Telsar Pharma, Inc., Acetylon Pharmaceuticals, Inc., Seldar Pharma, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.